Erectile Dysfunction Drugs Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Centers for Disease Control and Prevention (CDC) National Center for Health Statistics, World Health Organization (WHO) Global Health Observatory, International Society for Sexual Medicine (ISSM), American Urological Association (AUA), European Association of Urology (EAU), Sexual Medicine Society of North America (SMSNA), International Diabetes Federation (IDF), World Heart Federation, EU Eurostat Health Database, and national health ministry reports from key markets. These sources were used to collect prescription data, regulatory approval timelines, clinical efficacy studies, comorbidity prevalence rates (diabetes, cardiovascular disease), demographic trends, and competitive landscape analysis for phosphodiesterase type 5 inhibitors, testosterone replacement therapies, alprostadil formulations, and vacuum erection devices.

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. Supply-side sources comprised CEOs, VPs of R&D, regulatory affairs chiefs, and commercial directors from generic pharmaceutical companies, contract manufacturing organizations (CMOs), and erectile dysfunction drug manufacturers. Demand-side sources included procurement leads from hospital systems, retail pharmacy chains, and digital health platforms, as well as board-certified urologists, endocrinologists, primary care physicians, medical administrators of men's health clinics, and pharmacy benefit managers. Market segmentation was validated across drug categories and administration routes, product pipeline timelines were confirmed, and insights on generic substitution patterns, pricing pressures, formulary placement strategies, and telemedicine adoption impacts on prescribing behaviors were gathered through primary research.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (30%), Director Level (35%), Others (35%)

• By Region: North America (40%), Europe (25%), Asia-Pacific (22%), Rest of World (13%)

Global market valuation was derived through revenue mapping and prescription volume analysis. The methodology included:

• Identification of 50+ key manufacturers across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

• Product mapping across PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil), testosterone replacement therapies (injections, gels, patches), alprostadil (injectable and intraurethral suppositories), and vacuum erection devices

• Analysis of reported and modeled annual revenues specific to erectile dysfunction drug portfolios, including branded and generic segments

• Coverage of manufacturers representing 75-80% of global market share in 2024

• Extrapolation using bottom-up (prescription volume × ASP by country/region, adjusted for generic penetration rates) and top-down (manufacturer revenue validation, adjusted for pipeline product probability-weighted net present value) approaches to derive segment-specific valuations by drug class, route of administration, and distribution channel